It’s time that medical science recognizes that men and women are biologically different. Women understand this, as they alone experience the symptoms of PMS and menopause, which over a lifetime can lead to changes in menstruation, disruption in sleep, physical discomfort, and mood.
We know women want solutions for the symptoms they experience, especially their emotional wellbeing, because we’ve asked them.
Here’s what we know today.
According to science, a lot of the symptoms women experience are due to fluctuating estrogen levels. While it’s more complex than stating that fluctuating estrogen always leads to emotional imbalance, research indicates that estradiol (the dominant subtype of estrogen) negatively impacts the serotonin system resulting in a diminished sense of wellbeing.
Unfortunately, up to 80% of all women, regardless of ethnicity, class, or country of origin, experience this disruption in emotional health during perimenopause and menopause.
Outside of anti-depressants, there are no other treatment options available for women experiencing the more challenging emotional symptoms of menopause. This mental health treatment gap represents a massive unmet need that affects over 1 billion women worldwide.
One of the critical properties of psychedelics is their positive impact on the serotonin system. The scientific goal of Eastra Health is the development of novel psychedelic-derived compounds formulated especially for women, which will address the negative impacts of low estrogen levels and activate the serotonin receptor system appropriately.